ReproNovo: Funding, Investors & Team (Sep 2026)
ReproNovo is changing the landscape of reproductive medicine and women's health by pushing boundaries and introducing cutting-edge treatments for infertility and uterine conditions such as adenomyosis. Our experienced international team is well-versed in reproductive medicine, drug development, regulatory strategy, and business development, with a successful history of bringing new therapies to the market. Backed by top investors, including Jeito Capital and M Ventures, our headquarters are in Lausanne, Switzerland, with development teams in Copenhagen, Denmark and Barcelona, Spain. Meet our leadership team: CEO & Co-Founder Jean Duvall, Chief Scientific & Medical Officer & Co-Founder Joan-Carles Arce, and Chief Financial Officer & Co-Founder BingMei Hao.
ReproNovo has raised $65.0M across 1 funding round on record, the most recent a Series A of $65.0M announced in May 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ReproNovo Company Profile and Key Stats
Latest funding round on record: May 2025.
ReproNovo Funding Rounds
ReproNovo Founders and Leadership Team
No contact details are on record for this team yet.
ReproNovo Funding Compared to Other Biotechnology Startups
ReproNovo's latest round of $65.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ReproNovo in Biotechnology and Lausanne
Companies Similar to ReproNovo
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
ReproNovo Funding FAQs
What does ReproNovo do?
ReproNovo is changing the landscape of reproductive medicine and women's health by pushing boundaries and introducing cutting-edge treatments for infertility and uterine conditions such as adenomyosis. Our experienced international team is well-versed in reproductive medicine, drug development, regulatory strategy, and business development, with a successful history of bringing new therapies to the market. Backed by top investors, including Jeito Capital and M Ventures, our headquarters are in Lausanne, Switzerland, with development teams in Copenhagen, Denmark and Barcelona, Spain. Meet our leadership team: CEO & Co-Founder Jean Duvall, Chief Scientific & Medical Officer & Co-Founder Joan-Carles Arce, and Chief Financial Officer & Co-Founder BingMei Hao.
How much funding has ReproNovo raised?
ReproNovo has raised $65.0M across 1 round on record. The most recent is a Series A of $65.0M announced in May 2025.
When did ReproNovo last raise funding?
ReproNovo's most recent funding round on record is a Series A of $65.0M, announced in May 2025.
Who founded ReproNovo?
FundedIQ lists Bingmei Hao (Founder) at ReproNovo.
Where is ReproNovo headquartered?
ReproNovo is based in Lausanne, Vaud, Switzerland.
How many employees does ReproNovo have?
ReproNovo is in the 11-50 employee band.
How does ReproNovo's funding compare to other Biotechnology startups?
ReproNovo's latest round of $65.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's ReproNovo Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ReproNovo is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.